Amylin Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Amylin Pharmaceuticals
Type Private
Industry Biotechnology
Founded 1987
Headquarters San Diego, California, USA
Key people Daniel M. Bradbury[1]
Products Symlin (pramlintide)
Byetta (exenatide)
Revenue IncreaseUS$758M (FY 2009)[2]
Operating income DecreaseUS$-173M (FY 2009)[2]
Net income DecreaseUS$-186M (FY 2009)[2]
Total assets IncreaseUS$1.73B (FY 2009)[3]
Total equity IncreaseUS$423M (FY 2009)[3]
Employees 1,900 [1]
Website www.amylin.com

Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs, Symlin (pramlintide acetate) and Byetta (exenatide) and Bydureon (exenatide extended-release). Amylin also produces an analog of human leptin, metreleptin.[4]

In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion.[5]

In December 2013, Amylin was acquired by AstraZeneca.[6]

References[edit]

External links[edit]